01—Abstract
Summary
Summary of the 10-K/A filed March 27, 2003. Cited figures are marked; the original filing is the authoritative source.
This filing is an amendment (10-K/A) to Thermo Fisher Scientific Inc.'s (TMO) annual report for the fiscal year ended December 28, 2002.
The primary purpose of this amendment is to provide updated exhibit information, specifically adding exhibits related to restricted stock agreements for key executives (Marc N. Casper and Guy Broadbent) and a description of the company's Supplemental Long Term Disability Plan. The company confirms its compliance with SEC filing requirements, stating it has filed all reports for the preceding 12 months and has been subject to filing requirements for at least the past 90 days, identifying itself as an accelerated filer.
Investors should note that this amendment primarily concerns administrative and disclosure-related updates rather than significant changes to the company's core financial performance or strategic direction for the 2002 fiscal year. The certifications from the CEO and CFO reaffirm the accuracy and completeness of the previously filed financial statements and disclosure controls, indicating no material issues were found during their review.
02—Key points
Key Highlights
- Amendment No. 1 to the Form 10-K for the fiscal year ended December 28, 2002, filed by Thermo Electron Corporation (now Thermo Fisher Scientific Inc.).
- The amendment introduces new exhibits: Restricted Stock Agreements for Marc N. Casper (February 26, 2003) and Guy Broadbent (October 13, 2000), and a Description of Supplemental Long Term Disability Plan.
- The company asserts it has met all filing requirements for the preceding 12 months and has been subject to filing requirements for over 90 days.
- Thermo Electron Corporation is identified as an 'accelerated filer' as of the filing date.
- Certifications from CEO Marijn E. Dekkers and CFO Theo Melas-Kyriazi attest to the fair presentation of financial statements and the effectiveness of disclosure controls and procedures.
- No material weaknesses in internal controls or significant fraud involving management were disclosed.
- The aggregate market value of the company's voting stock held by non-affiliates was approximately $2.77 billion as of June 28, 2002.
03—Questions
Frequently Asked Questions
What is the main purpose of this filing (10-K/A)?
This filing is an amendment (10-K/A) to Thermo Fisher Scientific Inc.'s (TMO) annual report for the fiscal year ended December 28, 2002. Its primary purpose is to add new exhibits, including restricted stock agreements for two executives and details on the company's supplemental long-term disability plan.
Does this amendment reveal any new financial performance information for fiscal year 2002?
No, this amendment primarily focuses on updating exhibit information and reaffirming previous disclosures. It does not introduce new core financial results or significant changes to the financial performance previously reported for fiscal year 2002. The certifications provided by the CEO and CFO relate to the accuracy of the existing financial information.
What is the significance of the restricted stock agreements mentioned?
The restricted stock agreements filed as exhibits indicate the company's use of equity-based compensation for key executives, Marc N. Casper and Guy Broadbent. These agreements typically outline the terms and conditions under which the stock is granted and vests, which can be important for understanding executive compensation and potential future share dilution.
Are there any concerns raised about the company's internal controls or financial reporting in this amendment?
No, the certifications from the CEO and CFO explicitly state that they have reviewed the annual report, found no untrue material statements or omissions, and that the financial statements fairly present the company's condition. They also confirmed no material weaknesses in internal controls or significant fraud were identified that would adversely affect the company's ability to report financial data.
04—Continue